Clinical Trials – Poznań, Poland      

Certus Hospital

Certus Hospital in Poznań is a modern medical facility which combines high quality health care with individual approach to each patient.

It offers a wide range of specializations, including orthopedics, gastrology, urology, general surgery, laryngology, and ophthalmology, as well as innovative treatment and diagnostic methods. Thanks to its team of experienced specialists and a state-of-art equipment, the hospital provides comprehensive care of the highest standards. Certus Hospital is a place where patients can find support on each stage of treatment, from diagnostics, to specialized procedures.

Clinical Trial Site by Certus Hospital actively supports medicine development in many key disciplines, such as gastroenterology, dermatology, neurology, cardiology, laryngology, allergology. With specialized care and innovative therapeutic solutions, patients can rely on effective treatment that is adjusted to their individual health needs.

The character of Certus Hospital and Our Clinics at ul. Marcelińska and at. ul. Wichrowe Wzgórze in Poznań ensures special support for our patients especially in areas in which their health requires special care, including:

  • Allergology,
  • Surgery,
  • Internal diseases,
  • Infectious diseases,
  • Dermatology,
  • Diabetology and Endocrinology,
  • Gastroenterology,
  • Gynecology,
  • Hepatology,
  • Cardiology,
  • Nephrology,
  • Neurology,
  • Orthopedics,
  • Pediatrics,
  • Pulmonology,
  • Psychiatry,
  • Urology.

Thanks to using state-of-art medical solutions, the site can offer our patients access to therapies which have often been unavailable before or have been difficult to access, allowing for the use of the most advanced treatment methods.

Address:

Address:
Grunwaldzka Street 156,
60-309 Poznań

View on Google Maps

Contact the Center:

Contact Hours:

Pon-pt: 7:00 – 15:00

Check the location of our center

We carry out clinical trials in the following therapeutic areas:

  • Gastroenterology
  • Neurology
  • Dermatology
  • Cardiology
  • Infectious Diseases
  • Otorhinolaryngology
  • Allergology
  • Internal Medicine

Center Infrastructure:

We have fully equipped medical and diagnostic offices adapted to conducting studies across various specialties. We focus on patient comfort and the ergonomics of the research team’s work by providing adequate space, modern solutions, and patient safety ensured through regular equipment inspections.

Diagnostyka

Diagnostics

high-quality endoscopy units, access to MRI/MRA, computed tomography (CT), fibroscope, ultrasound/X-ray, and spirometry.

Specjalistyczne urządzenia laboratoryjne

Specialized Laboratory Equipment

• Refrigerator with continuous temperature monitoring
• –20°C freezer with continuous temperature monitoring
• 12-lead ECG
• Scale
• Height measuring device (stadiometer)
• Centrifuge
• Blood pressure monitor
• Thermometers for measuring patient body temperature
• Thermometers for continuous monitoring of medication storage temperature (2–25°C)

W pełni wyposażone gabinety lekarskie i diagnostyczne

Fully Equipped Medical and Diagnostic Offices

Adapted for conducting studies across various specialties. We focus on patient comfort and the ergonomics of the research team’s work by providing adequate space and modern solutions.

Nowoczesne sale konsultacyjne

Modern Consultation Rooms

for physicians and patients

Dedykowany dział farmacji

Dedicated Pharmacy Department

meets the highest standards for drug storage and preparation. Thanks to a laminar airflow hood, we can safely prepare biological products, and restricted access to the Investigational Product ensures full control over research products.

The center meets the highest storage standards, and restricted access to the Investigational Product ensures full control over research products. All facilities are adapted to the requirements of GCP (Good Clinical Practice)–compliant clinical trials and provide comfort and safety for participants.

Our Specialists:

Our greatest asset is an experienced and dedicated team.

Our staff consists of seasoned specialists who combine clinical expertise with proficiency in conducting clinical trials in accordance with GCP (Good Clinical Practice) and international standards.

Physicians

in the fields of gastroenterology, dermatology, neurology, cardiology, otolaryngology, and allergology.

Coordinators

clinical trial coordinators with many years of experience in managing documentation, study schedules, and participant care;

Nurses and Pharmacists

Qualified nursing staff and pharmacists trained in clinical protocols and participant safety.

Quality Control:

Our operational structure is based on clearly defined processes that comply with international GCP standards. A strong focus on quality is the foundation of our clinical trials, ensuring full data integrity and patient safety.

Quality Specialist

Supervision of quality processes is carried out by a qualified specialist responsible for monitoring compliance with international standards, conducting internal audits, and coordinating corrective actions.

Process Management System

We implement a comprehensive process management system that enables precise mapping and monitoring of all activities related to clinical trials. This ensures full compliance with internal procedures and high operational efficiency.

Internal Training

We regularly conduct specialized quality training to ensure that all members of our team are up to date with the latest requirements and best practices in quality management.

Standard Operating Procedures (SOPs)

At Penta Hospitals Poland, every activity—regardless of its scale—is precisely defined within the Standard Operating Procedures (SOPs). These documents are regularly updated to meet evolving regulatory requirements, ensuring operational continuity and consistency at every stage of clinical trial execution.

List of Clinical Trials Conducted at the Center

Gastroesophageal reflux disease (GERD)

Gastroesophageal reflux disease is a chronic condition in which the stomach content flows back into the esophagus. It causes irritation of its mucous membrane and shows most frequently as heartburn, retrosternal pain, burping, or regurgitation.

Clinical trials – Ulcerative colitis

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that causes inflammation and ulceration in the lining of the large intestine (colon).

Clinical trial – Crohn’s disease

Crohn's disease is a chronic inflammatory bowel disease that can affect any part of the digestive tract, from the mouth to the anus, although it most often affects the final section of the small intestine (ileum) and the initial part of the large intestine.

Clinical trials – type 2 diabetes with a risk of heart failure

Type 2 diabetes significantly increases the risk of heart failure, as long-term increased blood sugar level leads to damaging blood vessels and the heart muscle. These processes cause inflammations and buildup of harmful substances in tissues, which weakens the heart’s function.

Clinical trials – Chronic kidney disease and hypertension

Chronic kidney disease (CKD) combined with hypertension (HTN) constitute a serious therapeutic challenge due to both conditional affecting each other mutually.

Clinical trials – Asthma

Asthma is a chronic inflammation of respiratory track, leading to its hyperresponsiveness and narrowing. It manifests itself with recurrent attacks of shortness of breath, wheezing, coughing, and chest tightness. The condition is often exacerbated by allergens, infections, or physical exertion.

Clinical trials – acne inversa

A chronic, inflammatory ski disease characterized by painful abscesses and fistulas, most often in the axillary, groin or submammary areas, which significantly reduces the quality of life and can lead to serious complications and scarring.

Clinical trials – COVID-19

COVID-19 disease caused by SARS-CoV-2 coronavirus mostly affects the respiratory system and can result in serious health consequences for older people and those with existing chronic diseases.

Clinical trials – Atopic dermatitis in adults

Atopic dermatitis is a condition that can impact the comfort of daily life. Unesthetic redness can affect the sick person's appearance, which can lead to lower self-esteem.

Hypertension in patients at risk of or diagnosed with cardiovascular disease

This condition requires careful monitoring and ongoing medical supervision, as elevated blood pressure significantly increases the risk of serious complications. If left untreated, hypertension may lead to myocardial infarction, stroke, heart failure, or kidney damage.

Secondary progressive non-relapsing multiple sclerosis (MS) is a form of MS in which an initial period of relapsing-remitting course of disease (RRMS) is followed by a gradual, continuous deterioration of neurological function without marked relapses.

Hives is a skin condition characterized by specific wheals, redness, and itching. Hives is often accompanied by swelling known as angioedema.

Trial in progress

Multiple sclerosis

Multiple sclerosis is a chronic, inflammatory, demyelinating disease of the central nervous system that causes multifocal damage to nerve tissue. The disease usually has a phasic course, with periods of exacerbation and remission.

Chronic sinusitis without nasal polyps is a long-term inflammation of the paranasal sinus mucosa that continues for at least 12 weeks without interruption.

RSV (Respiratory Syncytial Virus) is a virus which causes respiratory system infections, especially dangerous for babies, small kids, and the elderly.

Completed trial

Meningococcal vaccine

The study aims to compare the effectiveness of two vaccines against meningococcal diseases types A, C, W-135 and Y – the investigational product MenQuadfi with the commercially available preparation Nimenrix

How to participate
in clinical trials

Step 1

Registration

Do you want to participate in a clinical trial? It’s simple. You just need to fill in a short registration form. Our team will contact you for an initial interview to check if the trial is suitable for you. Don’t worry, we will answer all your questions!

Step 2

Appointment with a doctor

After the initial qualification, we will invite you for an appointment with a doctor conducting the trial. The doctor will be available for you to tell you more about the trail, discuss any possible doubts and check the condition of your health.
The appointment is free-of-charge and non-committal.

Step 3

Decision

You are completely free to make your own decision about participating in the trial. After the meeting, you will have time to think through all the information. If you decide to participate, we will sign suitable documents and get you ready for next steps.

Step 4

Participation in the trial

After you make a decision, the actual part of the trial starts. You can always count on our support and use regular consultations.

Clinical Trial Coordinators in Poznań

Kinga Kierończyk - Manager Ośrodka Badań Klinicznych

Kinga Kierończyk

Clinical trial site manager
Default Avatar

Karolina Osmólska-Cholewa

Clinical trial coordinator
Default Avatar

Katarzyna Giezek

Clinical trial coordinator
Default Avatar

Anna Ciołek

Clinical trial coordinator

Didn’t Find a Clinical Trial You’re Interested In?

Contact us

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